

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/564,458
---------------------------	------------

<b>Filing Date</b>	July 22, 2004
--------------------	---------------

<b>First Named Inventor</b>	Anderson, Annaliesa S. et al,
-----------------------------	-------------------------------

## Group Art Unit

Examiner Name


Sheet

1

of

3

Attorney Docket Number 21569YP



## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		WO	2003/011899		University of Sheffield; Biosynexus Incorporated	02/13/2003
		WO	2002/102829		Inhibitex, Inc.; The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queens Elizabeth	12/27/2002
					Near Dublin; Universita Degli Studi Di Pavia	
		WO	02/094868		Chiron SRL.	11/28/2002
		WO	02/077183		Elitra Pharmaceuticals, Inc.	10/03/2002
		WO	02/059148 A3		Intercell AG	08/01/2002
		WO	02/059148 A2		Cistem Biotechnologies GMBH	08/01/2002
		WO	01/98499		University of Sheffield; Biosynexus Incorporated	12/27/2001
		EP	0 786 519		Human Genome Sciences, Inc.	07/03/1997
		PCT	WO2007/089470A2		Merck & Co., Inc.	08/09/2007

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 12/1/2007

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/564,458
				Filing Date	July 22, 2004
				First Named Inventor	Anderson, Annaliesa S. et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	21569YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Andrade, M. et al. "NEAT: a domain duplicated in genes near the components of a putative Fe <sup>3+</sup> siderophore transporter from Gram-positive pathogenic bacteria", Genome Biology, 2002, Vol. 3, pp. 0047.1-0047.5
		Baba, T. et al. "Genome and virulence determinants of high virulence community-acquired MRSA", The Lancet, 2002, Vol. 359, pp. 1819-1827
		Buckholz, R. et al. "Yeast Systems for the Commercial Production of Heterologous Proteins", Bio/Technology, 1991, Vol. 9, pp. 1067-1072
		Eckart, M. et al. "Quality and authenticity of heterologous proteins synthesized in yeast", Current Opinion in Biotechnology, 1996, Vol. 7, pp. 525-530
		Etz, H. et al. "Identification of <i>in vivo</i> expressed vaccine candidate antigens from <i>Staphylococcus aureus</i> ", PNAS, 2002, Vol. 99, pp. 6573-6578
		Fattom, A. et al. "Synthesis and Immunologic Properties in Mice of Vaccines Composed of <i>Staphylococcus aureus</i> Type 5 and Type 8 Capsular Polysaccharides Conjugated to <i>Pseudomonas aeruginosa</i> Exotoxin A", Infection and Immunity, 1990, Vol. 58, pp. 2367-2374
		Josefsson, E. et al. "Protection against Experimental <i>Staphylococcus aureus</i> Arthritis by Vaccination with Clumping Factor A, a Novel Virulence Determinant", The Journal of Infectious Diseases, 2001, Vol. 184, pp. 1572-1580
		Kersten, G. et al. "Liposomes and ISCOMs", Vaccine, 2003, Vol. 21, pp. 915-920
		Klein, J. et al. "Analysis of Aluminum Hydroxyphosphate Vaccine Adjuvants by 27A1 MAS NMR", Journal of Pharmaceutical Sciences, 2000, Vol. 89, pp. 311-321
		Kuroda, M. et al. "Whole genome sequencing of meticillin-resistant <i>Staphylococcus aureus</i> ", The Lancet, 2001, Vol. 357, pp. 1225-1240
		Lathe, R. "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data Theoretical and Practical Considerations", J. Mol. Bio., 1985, Vol. 183, pp. 1-12
		Mamo, W. et al. "Vaccination with <i>Staphylococcus aureus</i> fibrinogen binding proteins (FgBPs) reduces colonisation of <i>S. aureus</i> in a mouse mastitis model", FEMS Immunology and Medical Microbiology, 1994, Vol. 10, pp. 47-54
		Mazmanian, S. et al. "Passage of Heme-Iron Across the Envelope of <i>Staphylococcus aureus</i> ", Science, 2003, Vol. 299, pp. 906-909
		Mazmanian, S. et al. "Sortase-catalysed anchoring of surface proteins to the cell wall of <i>Staphylococcus aureus</i> ", Molecular Microbiology, 2001, Vol. 40, pp. 1049-1057
		Morrissey, J. et al. "Conservation, Surface Exposure, and In Vivo Expression of the Frp Family of Iron-Regulated Cell Wall Proteins in <i>Staphylococcus aureus</i> ", Infection and Immunity, 2002, Vol. 70, pp. 2399-2407

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 12/1/2007

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>COMPLETE IF KNOWN</b>		
			Application Number	10/564,458	
			Filing Date	July 22, 2004	
			First Named Inventor	Anderson, Annaliesa S. et al.	
			Group Art Unit		
			Examiner Name		
Sheet	3	of	3	Attorney Docket Number	21569YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Nilsson, I. et al. "Vaccination with a Recombinant Fragment of Collagen Adhesin Provides Protection against <i>Staphylococcus Aureus</i> -mediated Septic Death", J. Clin. Invest., 1998, Vol. 101, pp. 2640-2649
		O'Hagan, D. "Recent Developments in Vaccine Delivery Systems", Current Drug Targets - Infectious Disorders, 2001, Vol. 1, pp. 273-286
		Pichuanes, S. et al. "Expression of Heterologous Gene Products in Yeast", Protein Engineering: Principles and Practice, Edited by Jeffrey L. Cleland and Charles S. Craik, 1996, Chapter 5, pp. 129-161
		Rimmelzwaan, G. et al. "A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines", Vaccine, 2001, Vol. 19, pp. 1180-1187
		Schneewind, O. et al. "Cell wall sorting signals in surface proteins of Gram-positive bacteria", The EMBO Journal, 1993, Vol. 12, pp. 4803-4811
		Sharp, P. et al. "Synonymous Codon Usage in <i>Saccharomyces cerevisiae</i> ", Yeast, 1991, Vol. 7, pp. 657-678
		Shinefield, H. et al. "Use of a <i>Staphylococcus Aureus</i> Conjugate Vaccine in Patients Receiving Hemodialysis", N. Engl. J. Med., 2002, Vol. 346, pp. 491-496
		Taylor, J. et al. "Transferrin binding in <i>Staphylococcus aureus</i> : involvement of a cell wall-anchored protein", Molecular Microbiology, 2002, Vol. 43, pp. 1603-1614
		Vogel, F. "Improving Vaccine Performance with Adjuvants", Clinical Infectious Diseases, 2000, Vol. 30, (Suppl 3), pp. S266-S270
	X	PCT/US2008/006791 International filing date 5/29/2008; ;Merck & Co., Inc.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 12/1/2007